Thummel, KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest. 2007;117:3176–3179CrossRefGoogle ScholarPubMed

,Food and Drug Administration (FDA). (March, 2003). Bioavailability and bioequivalence studies for orally administered drug products – General considerations. Rockville, MD: FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (Last accessed August 13, 2009)

Ganapathy, V, Prasad, PD, Ganapathy, ME, Leibach, FH. Placental transporters relevant to drug distribution across the maternal–fetal interface perspectives in pharmacology. J Pharmacol Exp Ther. 2000;294:413–420Google Scholar

Ambudkar, SV, Dey, S, Hrycyna, CA, Ramachandra, M, Pastan, I, Gottesman, MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–398CrossRefGoogle ScholarPubMed

Atkinson, Jr Arthur J.. Clinical pharmacokinetics. Atkinson, AJ., Abernethy, DR, Daniels, CE, Dedrick, RL, Markey, SP. Principles of Clinical Pharmacology, Second Edition (2007), Academic Press; Burlington, MA; p. 11–23CrossRefGoogle Scholar

Gonzalez, Frank J, Tukey, Robert H. Drug metabolism. LL Brunton, JS Lazo, KL Parker. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e. (2006), McGraw Hill; New York; p. 71–91Google Scholar

Jones, PM, George, AM. The ABC transporter structure and mechanism: Perspectives on recent research. Cell Mol Life Sci. 2004;61(6):682–699CrossRefGoogle ScholarPubMed

Ringseis, R, Posel, S, Hirche, F, Eder, K. Treatment with pharmacological peroxisome proliferator-activator receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats. Pharmacol Res. 2007;56:175–183CrossRefGoogle Scholar

Flockhart, DA, Bertilsson, L. Clinical pharmacogenetics. Atkinson, AJ., Abernethy, DR, Daniels, CE, Dedrick, RL, Markey, SP. Principles of Clinical Pharmacology, 2nd edition (2007), Academic Press; Burlington, MA; p. 179–195CrossRefGoogle Scholar

Aklillu, E, Persson, I, Bertilsson, L, Johansson, I, Rodrigues, F, Ingelman-Sundberg, M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278(1):441–446Google Scholar

Wang, JH, Li, PQ, Fu, QY, Li, QX, Cai, WW. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. Clin Exp Pharmacol Physiol. 2007;34(5–6):421–424CrossRefGoogle ScholarPubMed

Desta, Z, Zhao, X, Shin, JG, Flockhart, DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–958CrossRefGoogle ScholarPubMed

Holford, Nicholas H, “Chapter 3. Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action” (Chapter). Katzung BG: Basic & Clinical Pharmacology, 11th edition: http://www.accessmedicine.com/content.aspx?aID=4513158.

Buxton, I.L.O. Pharmacokinetics and pharmacodynamics: The dynamics of drug absorption, distribution, action, and elimination. Brunton, LL, Lazo, JS, Parker, KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition., (2006), McGraw Hill; New York; p. 1–39Google Scholar

Atkinson, AJ. Clinical pharmacokinetics. Atkinson, AJ., Abernethy, DR, Daniels, CE, Dedrick, RL, Markey, SP. Principles of Clinical Pharmacology, 2nd edition (2007), Academic Press; Burlington, MA; p. 11–23CrossRefGoogle Scholar

Collins, JM. Phase I clinical studies. Atkinson, AJ., Abernethy, DR, Daniels, CE, Dedrick, RL, Markey, SP. Principles of Clinical Pharmacology, 2nd edition (2007), Academic Press; Burlington, MA; p. 473–478CrossRefGoogle Scholar

,Food and Drug Administration (FDA). (July, 2005). Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville (MD): FDA. Last accessed August 13, 2009, from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf

Omura, GA. Modified Fibonacci search. J Clin Oncol. 2003;21:3177CrossRefGoogle ScholarPubMed

Collins, JM, Zaharko, DS, Dedrick, RL, Chabner, BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986;70(1):73–80Google ScholarPubMed

Eisenhauer, EA, O'Dwyer, PJ, Christian, M, Humphrey, JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18:684–692CrossRefGoogle ScholarPubMed

,Food and Drug Administration (FDA). (January, 2006). Exploratory IND Studies. Rockville (MD): FDA. Last accessed August 13, 2009, from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078933.pdf

Collins, JM. Phase 0 clinical studies in oncology. Clin Pharmacol Ther. 2009;85:204–207CrossRefGoogle Scholar

Woodcock, J. Chutes and ladders on the critical path: Comparative effectiveness, product value, and the use of biomarkers in drug development. Clin Pharmacol Ther. 2009;86:12–14CrossRefGoogle ScholarPubMed

Uppoor, RS, Mummaneni, P, Cooper, E, Pien, HH, Sorensen, AG, Collins, J, Mehta, MU, Yasuda, SU. The use of imaging in the early development of neuropharmacological drugs: A survey of approved NDAs. Clin Pharmacol Ther. 2008;84:69–74CrossRefGoogle ScholarPubMed

Collins, JM. Imaging and other biomarkers in early clinical studies: One step at a time or re-engineering drug development?J Clin Oncol. 2005;23:5417–5419CrossRefGoogle ScholarPubMed

Dreisbach, AW, Lertora, JJL. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065–1074CrossRefGoogle ScholarPubMed

,National Kidney Foundation. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Last accessed August 13, 2009, from: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p5_lab_g4.htm

,National Kidney Disease Education Program: GFR Calculators for Children. Last accessed August 13, 2009, from: http://www.nkdep.nih.gov/professionals/gfr_calculators/gfr_children.htm

,Food and Drug Administration (FDA). (November, 1998). Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. Rockville (MD): FDA. Last accessed August 13, 2009, from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf

Fox, E, Balis, FM. Drug therapy in neonates and pediatric patients. Atkinson, AJ., Abernethy, DR, Daniels, CE, Dedrick, RL, Markey, SP. Principles of Clinical Pharmacology, 2nd edition (2007), Academic Press; Burlington, MA; p. 359–373CrossRefGoogle Scholar